Navigation Links
NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
Date:2/18/2011

to 85% of subjects which indicates that the VLP vaccine will be important in addressing future influenza pandemics.  Novavax VLPs are unique as they are made in a non-egg-based, recombinant manufacturing system that produces particles resembling the influenza virus but which renders them more immunogenic than simple recombinant vaccines."

Methods

This Phase II randomized, double-blind, placebo-controlled trial was conducted at a single study center in Mexico to evaluate the safety, tolerability, and immunogenicity of 3 dose levels (5mcg, 15mcg, and 45mcg HA) of the novel (H1N1) influenza VLP vaccine as compared with a placebo in healthy adults aged 18 to 64 years.  The study was conducted in two parts: Part A was to evaluate the safety and immunogenicity of the H1N1 influenza VLP vaccine over a dose range and to select a dose for an expanded safety evaluation in Part B. In Part A, 1,013 subjects were enrolled (760 active and 253 placebo). Based on an interim safety and immunogenicity analysis, an additional 3,547 (2,535 active and 1,012 placebo) subjects were enrolled in Part B of the study, a safety only study, and received 15mcg of VLP vaccine or placebo as a single injection on Day 1 using a second lot of H1N1 VLP vaccine.

Safety

In Part A, adverse events (AEs) were similar for the placebo group and for the active vaccine groups, except that dose-related local injection site reactions were reported more frequently in the active vaccine groups.  In Part B of the study, the incidence of AEs was consistent with that of Part A and was comparable between the VLP and placebo groups.  The results for the 15mcg vaccine in Part A and Part B of the study demonstrated that the different vaccine lots exhibited comparable safety profiles.  Across all subjects in Part A and Part B, the majority of AEs were of mild or moderate severity and resolved without sequelae and all serious AEs were considered defin
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
2. NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
3. NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
4. NOVAVAX Reports Third Quarter 2010 Financial Results
5. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
6. NOVAVAX to Present at BIO Investor Forum
7. NOVAVAX to Present at Stifel Nicolaus Conference
8. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
9. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 ... some of our Medicare resources and continue highlighting the success of the prescription drug ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... announces that a new market research report is ... Triple Analysis: Leukemia, Prostate Cancer and Apoptosis ... This triple analysis focuses on cancer drug development ... by the mechanism/target/effect of Apoptosis. Each of these ...
... SILVER SPRING, Md., May 3, 2011 The U.S. ... Commission (FTC) today announced a joint effort to remove ... treat, cure, and prevent sexually transmitted diseases (STDs). Among ... Viruxo, C-Cure, and Never An Outbreak. (Logo: ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 2Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 3Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 4FDA, FTC Act To Remove Fraudulent STD Products From The Market 2FDA, FTC Act To Remove Fraudulent STD Products From The Market 3
(Date:7/30/2015)... ... July 30, 2015 , ... The connection between a healthy head of hair and a feeling ... a full head of hair can have a devastating impact on the daily life of ... the work place, the consequences of hair loss are not to be taken lightly. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual intended to symbolize a ... Treatment Center have created an addiction graveyard. Sharing this with the public comes at ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he ...
(Date:7/30/2015)... ... , ... The American Telemedicine Association (ATA) is seeking presentations ... on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 attendees ... 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s most ...
(Date:7/30/2015)... ... 2015 , ... " DevExpress ” was featured on NewsWatch ... medium, and large businesses making an impact in their industry. Susan Bridges, a ... with viewers how DevExpress has provided software development tools that have helped app ...
(Date:7/30/2015)... (PRWEB) , ... July 30, ... ... released a video, “Beachside Nursing Center,” to announce its position as one ... ratings. Beachside's administrator and staff members support the CMS rating system, which ...
Breaking Medicine News(10 mins):Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2
... begun to help,United Healthcare Workers-West members fight unprecedented ... International Union President and,Secretary-Treasurer., "A Salute to ... Health Care Workers-West and their President, Sal Rosselli, ... at the Julia Morgan,Ballroom, Merchants Exchange Building, 465 ...
... Lasers Limited (ASX:,ELX), a global leader in the ... today announced the six-month clinical study results,for the ... annual meeting of the American Academy of Ophthalmology.,The ... FRCPath,FRCOphth (Hons), of St. Thomas, Hospital, London, under ...
... E, C did little to protect healthy men, either ... studies released Sunday cast doubt on the cardiac benefits ... Japanese researchers found that low-dose aspirin did not reduce ... 2 diabetes. , Second, Harvard researchers concluded that neither ...
... to foil a tumor from generating blood vessels to feed ... creating drugs aimed at stopping a key vessel growth-promoting protein. ... Researchers at the Moores Cancer Center at the University of ... that blocking that protein target, called VEGF, or vascular endothelial ...
... Room #283-285, Ernest N. Morial Convention Center) , A team ... five key proteins out of thousands secreted into blood draining ... certain quantities form the basis of a far more accurate ... attack in people with severely reduced blood flow, or ischemia. ...
... less likely than Caucasian patients to undergo coronary ... successful angioplasty, a type of percutaneous coronary intervention ... Hispanics also had a trend toward lower ... and bypass surgery, according to a study presented ...
Cached Medicine News:Health News:Health Care Workers Get Help Fighting Unprecedented Attacks from Service Employee International Union Leadership 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Cancer drugs my build and not tear down blood vessels 2Health News:Cancer drugs my build and not tear down blood vessels 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 2Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 4Health News:Hispanics less likely to have repeat revascularizations 1 year after angioplasty 2
... Immunoassay Control is a ... designed to complement the ... Immunoassay Plus Controls. This ... to include more complex ...
Liquichek Hematology-8 Control is a whole blood hematology control with extended stability for non-differential analyzers....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: